The evaluation of the effect of the drug “Arthritan” on the morphofunctional state of the internal organs of rats under the conditions of the chronic toxicity study
DOI:
https://doi.org/10.24959/cphj.18.1477Keywords:
“Arthritan”, chronic toxicity, rats, histomorphological researchAbstract
Today, there is a growing demand for products for a healthy lifestyle and among them for natural products: more than 80 % of the world’s population use drugs of the plant origin for therapeutic and/or prophylactic purposes.
Aim. To study the effect of the drug “Arthritan” on the morphological structure of the internal organs of rats under the conditions of the chronic toxicity study.
Materials and methods. The study of the chronic toxicity of the drug “Arthritan” was performed on 80 nonlinear white rats of both sexes with daily intragastric administration for 6 months. The histomorphological study of the internal organs was carried out using the standard methods of light microscopy.
Results. Under the effect of the test drug “Arthritan” with chronic intragastric administration in all doses studied there are no significant changes in the morphofunctional state of the internal organs of rats, and it indicates the absence of the cardio-, hepato- and nephrotoxic action, as well as the negative effect on the central nervous, endocrine and immune systems, and characterizes this remedy as highly safe in prolonged use even in ultra-high doses.
Conclusions. With chronic intragastric administration in rats for 180 days the drug “Arthritan” in the doses of 0.1, 0.2 and 0.5 ml/kg does not cause the death of animals, does not have a toxic effect on the general condition, behavior and dynamics of the body weight, does not cause significant differences in the indices of laboratory analyses of urine and blood, practically does not affect the functional state of the urinary and hepatobiliary systems of animals.
References
Serhyenko, O. M., Zhyhunova, A. K. (2013). Ukrainskyi medychnyi chasopys, 1, 77–80.
Harnyk, T. P., Tumanov, V. A., Pokanevych, V. V., Frolov, V. M., Peresadin, M. O. (2012). Fitoterapiia. Chasopys, 1, 4–11.
WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. (2017). World Health Organization, 118.
Kunle, O. F., Egharevba, H. O., Ahmadu, P. O. (2012). Standardization of herbal medicines - A review. International Journal of Biodiversity and Conservation, 4(3), 101–112. https://doi.org/10.5897/ijbc11.163
Tattis, A., Zupanets, I. A., Otrishko, I. A., & Grintsov, I. F. (2015). The study of the safety profile of “Altsinara” drug under the conditions of acute toxicity modeling. Klìnìčna farmacìâ, 19(3), 44–47. https://doi.org/10.24959/cphj.15.1350
Tattis, A., Zupanets, I. A., Shebeko, S. K., Otrishko, I. A., Hrintsov, Ye. F. (2015). Odeskyi medychnyi zhurnal, 6 (152), 37–42.
Tattis, A., Zupanets, I. A., Shebeko, S. K., Otrishko, I. A., Grintsov, Ie. F. (2015). Study of lipid-lowering activity of the drug «Altsinarа» in the experiment. The Pharma Innovation Journal, 4 (8), 77–80.
Zupanets, I. A., Tattis, A., Shebeko, S. K., Otrishko, I. A., Hrintsov, Ye. F., Dobrovolnyi, O. O., Fesenko, S. O., Shalamai, A. S., Shylkina, O. O. (2016). Rozrobka efektyvnykh zasobiv hipolipidemichnoi ta antyaterohennoi dii na osnovi ekstraktu artyshoku ta poroshku chasnyku. Informatsiinyi lyst pro novovvedennia v sferi okhorony zdorovia № 194-2016. Ukrmedpatentinform MOZ Ukrainy. Vypusk z problemy «Klinichna farmakolohiia i klinichna farmatsiia», Kyiv, 3.
Nastanova ST-N MOZU 42-7.0:2008 «Likarski zasoby. (2009). Nalezhna klinichna praktyka», 48.
ICH E6: Good Clinical Practice: Consolidated guideline, CPMP/ICH/135/95. (n.d.).
Helsinskaya deklaratsiya Vsemirnoy meditsinskoy assotsiatsii. Eticheskie printsipyi provedeniya meditsinskih issledovaniy s uchastiem cheloveka v kachestve sub'ekta (2013).
Lapach, S. N., Chubenko, A. V., Babych, P. N. (2002). Osnovnye printcipy primeneniia statisticheskikh metodov v klinicheskikh ispytaniiakh. Kyiv: MORION, 160.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
